Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer.
A2aR
CD276
CD80
CTLA-4
IDO1
Immune checkpoint
Immune checkpoint imaging
OX40
PD-1
PD-L1
PET
SPECT
Tumor expression
Journal
EJNMMI radiopharmacy and chemistry
ISSN: 2365-421X
Titre abrégé: EJNMMI Radiopharm Chem
Pays: England
ID NLM: 101714628
Informations de publication
Date de publication:
06 Nov 2019
06 Nov 2019
Historique:
received:
17
05
2019
accepted:
21
09
2019
entrez:
8
11
2019
pubmed:
7
11
2019
medline:
7
11
2019
Statut:
epublish
Résumé
Immunotherapy with checkpoint inhibitors demonstrates impressive improvements in the treatment of several types of cancer. Unfortunately, not all patients respond to therapy while severe immune-related adverse effects are prevalent. Currently, patient stratification is based on immunotherapy marker expression through immunohistochemical analysis on biopsied material. However, expression can be heterogeneous within and between tumor lesions, amplifying the sampling limitations of biopsies. Analysis of immunotherapy target expression by non-invasive quantitative molecular imaging with PET or SPECT may overcome this issue. In this review, an overview of tracers that have been developed for preclinical and clinical imaging of key immunotherapy targets, such as programmed cell death-1, programmed cell death ligand-1, IDO1 and cytotoxic T lymphocyte-associated antigen-4 is presented. We discuss important aspects to consider when developing such tracers and outline the future perspectives of molecular imaging of immunotherapy markers. Current techniques in immune checkpoint imaging and its potential for future applications.
Identifiants
pubmed: 31696402
doi: 10.1186/s41181-019-0078-z
pii: 10.1186/s41181-019-0078-z
pmc: PMC6834817
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
29Subventions
Organisme : KWF Kankerbestrijding (NL)
ID : 10099
Organisme : Innovative Medicines Initiative ()
ID : 116106
Organisme : Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NL)
ID : 91617039
Références
Bioconjug Chem. 2018 Oct 17;29(10):3476-3482
pubmed: 30227708
Oncoimmunology. 2012 Nov 1;1(8):1223-1225
pubmed: 23243584
Neuro Oncol. 2014 Oct;16(10):1373-83
pubmed: 24670609
Nucl Med Biol. 2012 Oct;39(7):926-32
pubmed: 22444239
J Nucl Med. 2015 Aug;56(8):1258-64
pubmed: 25952734
Cell Physiol Biochem. 2018;47(2):721-734
pubmed: 29794465
Am J Cancer Res. 2019 Jan 01;9(1):53-63
pubmed: 30755811
Ann Nucl Med. 2002 Nov;16(7):467-75
pubmed: 12508837
J Clin Invest. 2007 May;117(5):1147-54
pubmed: 17476344
PLoS One. 2011 Feb 28;6(2):e17338
pubmed: 21386999
Sci Rep. 2015 Nov 10;5:16417
pubmed: 26552594
J Labelled Comp Radiopharm. 2018 Sep;61(11):826-836
pubmed: 29923634
J Nucl Med. 2017 May;58(5):762-767
pubmed: 28062599
Mol Pharm. 2018 Apr 2;15(4):1674-1681
pubmed: 29502426
Nucl Med Biol. 2016 Jun;43(6):379-89
pubmed: 27260779
J Nucl Med. 2000 Feb;41(2):345-54
pubmed: 10688121
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
Theranostics. 2016 Jun 18;6(10):1629-40
pubmed: 27446497
Synapse. 2007 Sep;61(9):778-84
pubmed: 17568431
Front Immunol. 2018 Aug 31;9:1909
pubmed: 30233564
Neuroimage. 2017 Aug 15;157:209-218
pubmed: 28583881
Biomed Res Int. 2014;2014:460654
pubmed: 25126561
J Clin Invest. 2018 Jun 1;128(6):2569-2580
pubmed: 29596062
J Nucl Med. 1998 Mar;39(3):498-503
pubmed: 9529299
Bioconjug Chem. 2018 Jan 17;29(1):96-103
pubmed: 29125731
J Nucl Med. 2017 Feb;58(2):208-213
pubmed: 27765857
J Cereb Blood Flow Metab. 2006 Mar;26(3):345-57
pubmed: 16079785
Clin Cancer Res. 2019 Mar 15;25(6):1774-1785
pubmed: 30373750
Eur J Nucl Med Mol Imaging. 2007 May;34(5):679-687
pubmed: 17171358
J Nucl Med. 2019 Sep;60(9):1213-1220
pubmed: 30796165
Cancer Immunol Res. 2019 Jan;7(1):150-161
pubmed: 30459153
EJNMMI Res. 2014 Dec 29;4(1):76
pubmed: 25621197
J Clin Oncol. 2016 Dec;34(34):4102-4109
pubmed: 27863197
J Cereb Blood Flow Metab. 2015 Jan;35(1):157-65
pubmed: 25370856
Nat Commun. 2018 Nov 7;9(1):4664
pubmed: 30405135
Int J Cancer. 2005 Nov 20;117(4):538-50
pubmed: 15912538
J Nucl Med. 2019 Aug;60(8):1174-1182
pubmed: 30733320
Cancer Biol Ther. 2013 Apr;14(4):333-9
pubmed: 23358471
Int J Mol Sci. 2018 Dec 02;19(12):null
pubmed: 30513816
Mol Imaging Biol. 2017 Dec;19(6):903-914
pubmed: 28247187
Bioconjug Chem. 2016 Sep 21;27(9):2103-10
pubmed: 27458027
Nucl Med Biol. 2017 Aug;51:10-17
pubmed: 28511073
Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):3912-3917
pubmed: 29581255
Cell Res. 2017 Aug;27(8):1034-1045
pubmed: 28685773
Bioconjug Chem. 2015 Oct 21;26(10):2062-9
pubmed: 26307602
Front Immunol. 2015 Jan 12;5:673
pubmed: 25628622
EJNMMI Res. 2016 Dec;6(1):1
pubmed: 26728358
Cancer Res. 2015 Jul 15;75(14):2928-36
pubmed: 25977331
Int Immunol. 2015 Jan;27(1):39-46
pubmed: 25323844
Cancer Res. 2016 Jan 15;76(2):472-9
pubmed: 26554829
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):743-750
pubmed: 30105585
PLoS One. 2014 Nov 03;9(11):e109866
pubmed: 25365349
J Nucl Med. 2017 Nov;58(11):1852-1857
pubmed: 28588151
J Med Chem. 2014 Nov 13;57(21):9204-10
pubmed: 25279444
Neuropharmacology. 2018 Dec;143:106-112
pubmed: 30253174
J Nucl Med. 2017 Sep;58(9):1464-1470
pubmed: 28280214
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):110-120
pubmed: 28821924
Nat Commun. 2017 Sep 21;8(1):647
pubmed: 28935898
Oncotarget. 2016 Mar 1;7(9):10215-27
pubmed: 26848870
Nat Rev Immunol. 2003 Dec;3(12):939-51
pubmed: 14647476
J Nucl Med. 2017 Jan;58(1):162-168
pubmed: 27493273
Theranostics. 2017 Apr 7;7(6):1524-1530
pubmed: 28529635
Oncoimmunology. 2017 May 19;6(7):e1329071
pubmed: 28811971
J Cereb Blood Flow Metab. 2013 Sep;33(9):1394-401
pubmed: 23695433
Cancer Immunol Immunother. 2005 Apr;54(4):307-14
pubmed: 15599732
J Nucl Med. 2018 Mar;59(3):529-535
pubmed: 29025984
EJNMMI Res. 2015 Mar 28;5:19
pubmed: 25918673
Biochem Biophys Res Commun. 2017 Jan 29;483(1):258-263
pubmed: 28025143
Mol Imaging Biol. 2017 Feb;19(1):90-99
pubmed: 27430577
J Nucl Med. 2009 Mar;50(3):356-63
pubmed: 19223408
J Clin Invest. 2019 Feb 1;129(2):616-630
pubmed: 30457978
Theranostics. 2018 Jul 30;8(15):4199-4209
pubmed: 30128047
Nat Med. 2018 Dec;24(12):1852-1858
pubmed: 30478423
Mol Imaging. 2016 May 05;15:
pubmed: 27151136
Lancet Oncol. 2017 Jul;18(7):895-903
pubmed: 28551359
Neurology. 2011 May 24;76(21):1811-6
pubmed: 21606452
Sci Transl Med. 2017 May 10;9(389):
pubmed: 28490665
J Nucl Med. 2017 Apr;58(4):538-546
pubmed: 27980047
Mol Imaging Biol. 2017 Apr;19(2):289-297
pubmed: 27539309
Front Oncol. 2018 Jul 06;8:264
pubmed: 30035102
J Cereb Blood Flow Metab. 2017 Feb;37(2):577-589
pubmed: 26917190
J Neurooncol. 2019 Jan;141(1):111-120
pubmed: 30415456
Mol Imaging Biol. 2018 Oct;20(5):696-704
pubmed: 30030697
J Med Chem. 2014 Aug 14;57(15):6765-80
pubmed: 25061687
J Nucl Med. 2017 Oct;58(10):1560-1566
pubmed: 28522738
Cancer Res. 2017 Dec 15;77(24):6795-6811
pubmed: 29247038
Mol Imaging Biol. 2017 Aug;19(4):589-598
pubmed: 27815661
J Nucl Med. 2017 Mar;58(3):466-472
pubmed: 27789720
Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1108-13
pubmed: 24390540
Int J Cardiol. 2014 Jul 1;174(3):503-15
pubmed: 24834996
Mol Pharm. 2017 May 1;14(5):1782-1789
pubmed: 28388076
Oncotarget. 2017 Jun 27;8(26):41932-41946
pubmed: 28410210
Ann Nucl Med. 2000 Apr;14(2):81-9
pubmed: 10830524
Ann Nucl Med. 2000 Aug;14(4):247-53
pubmed: 11023024
J Nucl Med. 2012 Jul;53(7):1058-64
pubmed: 22653792
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
Mol Imaging Biol. 2019 Dec;21(6):1138-1146
pubmed: 30815792
Oncotarget. 2017 Jul 18;8(29):46900-46914
pubmed: 28159919
Ann Oncol. 2018 Jan 1;29(1):84-91
pubmed: 29228097
EJNMMI Res. 2017 Dec;7(1):57
pubmed: 28721684
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):278-87
pubmed: 25359636
Ann Nucl Med. 1997 Aug;11(3):219-25
pubmed: 9310171
Mol Pharm. 2018 Sep 4;15(9):3946-3952
pubmed: 30037229
Sci Rep. 2018 Jan 12;8(1):633
pubmed: 29330552